A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This phase 1 single ascending dose study will provide a first in human assessment of safety
and tolerability of PF-06755347 in healthy adult male subjects. The pharmacokinetics and
pharmacodynamics will also be evaluated.